研究課題/領域番号 |
19K16699
|
研究機関 | 東京医科大学 |
研究代表者 |
尹 晶煥 東京医科大学, 医学部, 兼任助教 (30748885)
|
研究期間 (年度) |
2019-04-01 – 2022-03-31
|
キーワード | Lung cancer / Anti-tumor immunity / Dendritic cell / T cell / TGF-beta / SMADs / STATs |
研究実績の概要 |
<Plan 1: Roles of SMADs in DCs and T cells in lung mucosal immune homeostasis> T cell and DC-specific Smad2 and Smad4 deficient (KO) mice showed normal immune phenotypes. Smad3 KO mice showed deficiency in a DC subset at the steady-state condition. <Plan 2: Roles of SMADs in DCs and T cells in lung cancer> I have established Lewis lung carcinoma cell line engineered to express GFP or the firefly luciferase gene (luc2) for orthotopic lung cancer model. <Plan 3: Effects of SMAD deficiency on STAT signaling in DCs and T cells in lung cancer> I have found that increased conventional DCs (cDCs) by SMAD3 deficiency showed significantly enhanced phosphorylation of STAT3. <Plan 4: Mechanisms how SMAD-STAT signaling networks regulate DCs and T cells in anti-lung cancer immunity> I have generated the various constitutively active or inactive mutants of SMADs or STAT3 using adeno-associated virus system.
|
現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
As stated in the summary, I have made a progress in accordance with the proposed plans.
|
今後の研究の推進方策 |
I will continue the research as proposed. I will finish revision of the submitted manuscript to publish the results on the role of SMAD3 on DC development (cf. Plan 1).
|
次年度使用額が生じた理由 |
Due to the pandemic, I could not spend all the fiscal budget. I will spend the balance for purchasing the antibodies and reagents required for the orthotopic Lewis lung carcinoma model and mechanistic studies this year.
|